ERBB2 and breast cancer: Despite these controversies, NCT remains an important treatment option for BC, and ongoing research is focused on identifying patient subgroups who may benefit the most from this approach.24 This study was conducted to evaluate the three-year survival of patients with HER2 negative BC who underwent NCT.